# **Product** Data Sheet



## (S,R,S)-AHPC-PEG2-C4-Cl

Cat. No.: HY-103607 CAS No.: 1835705-57-1

Molecular Weight: 651.26

Molecular Formula:

Target: E3 Ligase Ligand-Linker Conjugates

 $C_{32}H_{47}CIN_4O_6S$ 

Pathway: **PROTAC** 

Storage: Pure form -20°C 3 years

4°C 2 years

-80°C In solvent 6 months

> -20°C 1 month

### **SOLVENT & SOLUBILITY**

DMSO : ≥ 50 mg/mL (76.77 mM) In Vitro

> H<sub>2</sub>O: 50 mg/mL (76.77 mM; Need ultrasonic) Ethanol: 50 mg/mL (76.77 mM; Need ultrasonic) \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.5355 mL	7.6774 mL	15.3548 mL
	5 mM	0.3071 mL	1.5355 mL	3.0710 mL
	10 mM	0.1535 mL	0.7677 mL	1.5355 mL

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

Description	(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of		
	linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based		
	linker.~(S,R,S)-AHPC-PEG2-C4-Cl~is~capable~of~inducing~the~degradation~of~GFP-HaloTag7~in~cell-based~assays Alice of the continuous con		

IC<sub>50</sub> & Target VHL

In Vitro

 $(S,R,S)-AHPC-PEG2-C4-Cl\ uses\ the\ VHL\ ligand\ [1].\ The\ linkers\ contain\ a\ mixture\ of\ hydrophobic\ and\ hydrophilic\ moieties\ to\ property of\ property.$ balance the hydrophobicity/hydrophilicity of the resulting hybrid compounds. PROTACs that induce the degradation of an oncogenic tyrosine kinase, BCR-ABL has been developed. (S,R,S)-AHPC-PEG2-C4-Cl can be attached to potent TKIs (bosutinib and dasatinib) that mediate the degradation of c-ABL and BCR-ABL by hijacking either CRBN or VHL E3 ubiquitin ligase<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES				
[1]. Craig Crews, et al. Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same. US20170121321A1.  [2]. Lai AC, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10.				
Caution: Product has not been fully va	lidated for medical applications. For research use only.			
Tel: 609-228-6898 Fax: 609-2				
Address: 1 Deer Park Dr, S	uite Q, Monmouth Junction, NJ 08852, USA			

Page 2 of 2 www.MedChemExpress.com